Incyte Reports 2020 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

Go back to Incyte Reports 2020 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

Incyte (INCY) Misses Q3 EPS by 52c

November 5, 2020 7:38 AM EST

Incyte (NASDAQ: INCY) reported Q3 EPS of $0.23, $0.52 worse than the analyst estimate of $0.75. Revenue for the quarter came in at $621 million versus the consensus estimate of $623.31 million.

2020... More